Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Spinraza to Hit Japan Market on August 30
August 28, 2017
-
REGULATORY MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
-
REGULATORY Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
-
REGULATORY Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
-
BUSINESS External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
-
TRENDS Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
August 22, 2017
-
REGULATORY MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
-
REGULATORY Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
-
TRENDS Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena
August 18, 2017
-
BUSINESS Harvoni Top-Selling Drug in Japan in FY2016, Opdivo Jumps but Drop Expected for FY2017: Jiho Tally
August 17, 2017
-
ACADEMIA Japan Gastric Cancer Association to Wait for Opdivo Nod before Guidelines Update, Keytruda Won’t Make It This Time
August 16, 2017
-
REGULATORY 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
-
REGULATORY NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
-
INTERVIEW Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President
August 14, 2017
-
REGULATORY Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
-
BUSINESS Growth of Global Products Outstrips Abilify Drop in Jan.-June: Otsuka
August 9, 2017
-
BUSINESS Astellas Looks to Be First to Market in HIF-PH Inhibitor Space
August 8, 2017
-
ACADEMIA NCCHD to Launch Panel to Study Real-World Drug Use in Children, Findings Might Be Used for Label Revisions
August 8, 2017
-
TRENDS Top Drugs Jostling for Higher Share amid Tepid Market, Trulicity Overtakes Victoza in GLP Space: April-June
August 7, 2017
-
REGULATORY (Update) Katsunobu Kato Tapped as New Health Minister
August 4, 2017
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…